COMMUNIQUÉS West-GlobeNewswire

TearLab Osmolarity System Launches in Brazil
28/02/2018
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX: TLB ) (“TearLab” or the “Company”) today announced that it plans to launch the TearLab Osmolarity System at the 2018 Simpósio [...]
Corium Announces Proposed Offering of $100 Million of Convertible Senior Notes; Receives FDA Feedback on Pilot Bioequivalence Study
28/02/2018
MENLO PARK, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI ), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty [...]
Zomedica Pharmaceuticals Corp. Announces Year End 2017 Financial Results
28/02/2018
ANN ARBOR, Mich., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V: ZOM ) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported [...]
Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
28/02/2018
- Results to Date Show AST-OPC1’s Favorable Safety Profile, Potential for Cell Engraftment and Improved Motor Function - - Multiple Additional Data Readouts from SCiStar Study Expected in 2018 into First Quarter of 2019 [...]
Clementia Reports 2017 Operating Results and Business Highlights
28/02/2018
Enrollment Underway in Palovarotene Phase 3 MOVE Trial for Fibrodysplasia Ossificans Progressiva (FOP) On-track to Enroll First Patient in Palovarotene Phase 2 MO-Ped Trial for Multiple Osteochondromas (MO) this Quarter [...]
Clementia annonce ses résultats financiers et faits saillants de 2017
28/02/2018
Recrutement en cours pour l'essai clinique de phase 3 MOVE sur le palovarotene chez les patients atteints de fibrodysplasie ossifiante progressive (FOP) En voie de recruter un premier patient pour l'essai de phase 2 MO- [...]
SeaSpine Announces Fourth Quarter and Full-Year 2017 Results and Issues 2018 Financial Guidance
28/02/2018
CARLSBAD, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE ), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
28/02/2018
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON ), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer [...]
Fulgent Genetics Reports Fourth Quarter and Full Year 2017 Financial Results
28/02/2018
Fourth Quarter of 2017 Results : Revenue of $4.3 million GAAP loss of $1.8 million, or $0.10 per share Non-GAAP loss of $1.0 million, or $0.06 per share Adjusted EBITDA loss of $952,000 Full Year 2017 Results : Revenue [...]
K2M Group Holdings, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results
28/02/2018
LEESBURG, Va., Feb. 28, 2018 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq: KTWO ) (the “Company” or “K2M”), a global leader of complex spine and minimally invasive solutions focused on achieving three- [...]
BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results
28/02/2018
CAMBRIDGE, Mass. and BEIJING, China, Feb. 28, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
Novavax NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine
28/02/2018
Phase 2 trial of NanoFlu vaccine expected to begin in third quarter of 2018 Given strength of trial data, Novavax has submitted detailed results for publication in peer-reviewed medical journal Company management to [...]
Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
28/02/2018
--Conference Call Today at 4:30 p.m. ET-- SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA ) today reported financial results for the fourth quarter and full [...]
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate Update
28/02/2018
BURNABY, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE ), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 financial and operating [...]
AxoGen, Inc. Reports 2017 Fourth Quarter and Full Year Financial Results
28/02/2018
Record Q4 Revenue of $17.0 million, representing 49% growth over prior year Record Full year 2017 Revenue of $60.4 million, representing 47% growth over prior year ALACHUA, Fla., Feb. 28, 2018 (GLOBE NEWSWIRE) -- AxoGen [...]
Merit Medical Reports Results for Fourth Quarter and Year Ended December 31, 2017; Merit Meets Range of 2017 Guidance; Gives 2018 Guidance
28/02/2018
Q4 2017 worldwide revenue of $190.9 million ($188.2 million on a comparable, constant currency* basis), up 21.0% as reported (up 19.3% on a comparable, constant currency* basis) over Q4 2016 FY 2017 worldwide revenue of [...]
University of Missouri Health Care Selects Cerner for Revenue Cycle Management
28/02/2018
KANSAS CITY, Mo., Feb. 28, 2018 (GLOBE NEWSWIRE) -- University of Missouri Health Care, in Columbia, has selected Cerner, a global leader in health care technology, to help manage revenue cycle performance across its [...]
Helsinn Files Petition for Writ of Certiorari for Supreme Court Review Regarding Patent Covering Aloxi® in the US Market
28/02/2018
Helsinn Files Petition for Writ of Certiorari for Supreme Court Review Regarding Patent Covering Aloxi® in the US Market Lugano, Switzerland, and Woodcliff Lake, N.J., February 28, 2018 - In response to the United [...]
Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido™ (lidocaine topical system) 1.8% for PHN Pain
28/02/2018
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) (“Sorrento”), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from the U.S. Food and [...]

Pages